Anti-PCSK9 Rabbit Polyclonal Antibody

Rabbit Polyclonal
WB
Citation tracking pending
Rabbit polyclonal antibodies targeting the propeptide domain of PCSK9, validated for Western blot.
Host
Rabbit, Polyclonal
Reactivity
Validated- Human Potential-Mouse, Rat, Pan
UniProt
Q8NBP7
Size
100ug
Cat. #
RP3PC9

In stock

SKU
RP-PC9

Options

As low as: $130.00

Target Overview

Proprotein convertase subtilisin/kexin type 9 (PCSK9, EC 3.4.21.-, UniProt Q8NBP7) is a secreted serine protease that regulates plasma cholesterol homeostasis by controlling hepatic low-density lipoprotein receptor (LDLR) levels. The 692-amino acid protein binds to LDLR family members—including LDLR, VLDLR, LRP1/APOER, and LRP8/APOER2—and promotes their degradation in acidic intracellular compartments. Unlike classical proteases, PCSK9 functions via a non-proteolytic mechanism, redirecting LDLR from the endosomal recycling pathway to lysosomal degradation through clathrin-mediated endocytosis. This activity reduces surface LDLR density and consequently elevates circulating LDL cholesterol. Beyond lipid metabolism, PCSK9 modulates neuronal apoptosis through LRP8/APOER2 signaling, regulates epithelial sodium channel degradation, and participates in the quality control of BACE1 biosynthesis. Gain-of-function mutations cause familial hypercholesterolemia, while loss-of-function variants confer protection against coronary artery disease, establishing PCSK9 as a therapeutic target for cholesterol management.

Background

PCSK9 operates through a distinct regulatory mechanism in which the secreted convertase binds to LDLR at the cell surface and accompanies the receptor through clathrin-coated pits into early endosomes. Rather than recycling to the plasma membrane, the PCSK9-LDLR complex traffics to lysosomes where both proteins are degraded. PCSK9 can induce ubiquitination of LDLR, further directing it toward proteasomal or lysosomal degradation pathways. This continuous removal of LDLR from the hepatocyte surface reduces the liver's capacity to clear LDL particles from circulation, directly elevating plasma cholesterol levels. The propeptide domain of PCSK9 functions as an intramolecular chaperone required for proper folding and autocatalytic cleavage in the endoplasmic reticulum, but remains non-covalently associated with the mature enzyme and influences its secretion and activity. The clinical relevance of PCSK9 emerged from human genetic studies linking rare coding variants to extremes of LDL cholesterol and cardiovascular risk. This discovery catalyzed development of monoclonal antibody inhibitors (evolocumab, alirocumab) and siRNA therapeutics (inclisiran) that reduce LDL cholesterol by 50-60% in patients unable to achieve targets with statins alone. Recent real-world data confirm that inclisiran, which silences hepatic PCSK9 mRNA, sustains durable LDL reduction with twice-yearly dosing, addressing adherence challenges in chronic lipid management. Oral small-molecule PCSK9 inhibitors such as MK-0616 are now in clinical development, offering alternative routes of administration. Beyond cardiovascular disease, Mendelian randomization studies have explored potential pleiotropic effects of PCSK9 inhibition on aging and cancer risk, though mechanistic understanding of these associations remains incomplete. Triple Point Biologics offers three rabbit polyclonal antibodies raised against the PCSK9 propeptide domain, validated for detection in Western blot, immunohistochemistry, and immunofluorescence applications. These reagents enable investigation of PCSK9 expression, localization, and post-translational regulation in cell and tissue models relevant to lipid metabolism and vascular biology.

References

  1. Connolly DL et al (2024) From clinical development to real-world outcomes with inclisiran. Curr Opin Lipidol. PubMed · DOI
  2. Siddiqui Z (2025) New Oral PCSK9 Inhibitor: "MK-0616". Cardiol Rev. PubMed · DOI
  3. Chen H et al (2023) Causal effects of lipid-lowering therapies on aging-related outcomes and risk of cancers: a drug-target Mendelian randomization study. Aging (Albany NY). PubMed · DOI
  4. Han J et al (2026) Lipid lowering in coronary artery disease - not just statins. Clin Med (Lond). PubMed · DOI

Additional Specifications

Gene Symbol PCKS9
UniProt ID Q8NBP7
Host Species Rabbit
Species Reactivity Validated- Human
Potential-Mouse, Rat, Pan
Pack Size 100ug
Immunogen (Propeptide domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 33-72.
Immunogen (CT domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 422-692.
Immunogen (Catalytic domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 33-504.
Alternate Names PCSK9, Proprotein convertase subtilisin/kexin type 9, Neural apoptosis-regulated convertase 1, NARC-1, Proprotein convertase 9, PC9, Subtilisin/kexin-like protease PC9

Frequently Asked Questions

What molecular weight band should I expect for PCSK9 on a Western blot?

PCSK9 migrates as a ~75 kDa band on reducing SDS-PAGE, corresponding to the mature cleaved form. The full-length precursor is 692 amino acids (~75 kDa calculated), but PCSK9 undergoes autocatalytic cleavage in the ER, removing its prosegment while remaining noncovalently associated. You may occasionally see the uncleaved zymogen at a similar molecular weight or degradation products under ~60 kDa depending on sample handling. Use liver lysate or HepG2 cells as positive controls; PCSK9 is highly expressed in hepatocytes and secreted, so serum samples also work well.

Does this PC-9 antibody work for mouse and rat samples or only human?

This antibody is validated for human PCSK9. Mouse and rat cross-reactivity are predicted based on sequence homology—human PCSK9 shares approximately 80 percent identity with mouse and rat orthologs—but we have not formally validated performance in these species. If you are working with rodent samples, start with the recommended 1:1000 dilution and run a positive control (mouse liver lysate) alongside your samples. Titre the antibody if background is high or signal is weak. We recommend confirming specificity with a blocking peptide or siRNA knockdown in your model system.

What is the recommended starting dilution for Western blot with this PC-9 antibody?

Start at 1:1000 dilution in your blocking buffer for Western blot. This polyclonal antibody has been validated at this concentration for detecting endogenous PCSK9 in human liver and hepatoma cell lysates. Incubate overnight at 4°C with gentle agitation. If signal is weak or you are working with low-expression samples, you can increase concentration to 1:500. Conversely, if background is high, dilute further to 1:2000. Use 5 percent non-fat milk or BSA in TBST for blocking; both work well with this antibody in our hands.

Can I use this antibody for immunohistochemistry or immunofluorescence on tissue sections?

Yes, Triple Point Biologics antibodies are typically validated for IHC and immunofluorescence in addition to Western blot. For IHC on paraffin-embedded sections, use antigen retrieval with citrate buffer (pH 6.0) and start with a 1:100 to 1:200 dilution. PCSK9 localizes primarily to hepatocytes in liver tissue and is also expressed in kidney and intestine. For immunofluorescence, begin with 1:100 dilution on fixed cells or cryosections. Validate staining specificity by comparing signal in PCSK9-expressing tissues (liver) versus low-expression controls (skeletal muscle).

What sample types and lysis conditions work best for detecting PCSK9?

PCSK9 is highly expressed in liver and readily detected in hepatocyte-derived cell lines like HepG2 or Huh7. Use RIPA buffer with protease inhibitors for total cell lysates; PCSK9 is both intracellular and secreted, so you can detect it in conditioned media as well. For serum or plasma samples, dilute 1:10 to 1:50 in sample buffer and load 2 to 5 microliters per lane. Avoid repeated freeze-thaw cycles, as PCSK9 stability can be compromised. If detecting secreted PCSK9, concentrate conditioned media by TCA precipitation or ultrafiltration to improve sensitivity.

Does PCSK9 have isoforms or splice variants I should be aware of?

PCSK9 exists primarily as a single functional isoform in humans. The protein undergoes autocatalytic cleavage between Gln152 and Ser153, separating the prosegment from the catalytic domain, but both fragments remain noncovalently associated in the mature secreted form. You will not see distinct isoform bands on a Western blot. However, post-translational modifications and partial degradation can produce minor species. Some commercial PCSK9 preparations contain recombinant furin-cleaved variants, so if you are using purified protein as a standard, verify the form provided by the supplier to match your experimental context.

How should I store this antibody and what is the expected shelf life?

Store the antibody at -20°C as supplied. Avoid repeated freeze-thaw cycles by making single-use aliquots upon receipt; divide the 100 microgram vial into 10 to 20 microliter aliquots in cryovials. Once thawed, an aliquot can be kept at 4°C for up to two weeks for convenience during active experiments. For long-term storage beyond six months, keep at -80°C. Do not add sodium azide if you plan to use the antibody for applications other than Western blot, as it can interfere with HRP-based detection in some protocols. Properly stored, polyclonal antibodies remain stable for several years.

What controls should I include to confirm specificity for PCSK9?

Include a positive control with high endogenous PCSK9 expression, such as HepG2 whole-cell lysate or human liver tissue lysate. As a negative control, use a tissue with low or absent PCSK9 expression like skeletal muscle or pre-treat cells with PCSK9-targeting siRNA to demonstrate signal reduction. A blocking-peptide control is valuable: pre-incubate the antibody with the immunizing peptide (if available from the supplier) and show loss of signal. If working with overexpression systems, compare vector-transfected versus PCSK9-transfected lysates. These controls collectively confirm that the observed band is specific to PCSK9.

Western blot validation for RP-PC9 — 2 panels across the domain-specific antibody variants. Each blot below shows the clone that validates a specific domain of the target protein.

PC-9: Propeptide domain — WB validation
WB · Panel 1 PC-9: Propeptide domain
PC-9: CT domain — WB validation
WB · Panel 2 PC-9: CT domain

Custom validation studies available on request — contact us.

Also known as:

  • PCSK9
  • Proprotein convertase subtilisin/kexin type 9
  • Neural apoptosis-regulated convertase 1
  • NARC-1
  • Proprotein convertase 9
  • PC9
  • Subtilisin/kexin-like protease PC9
  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →